Global liver cancer diagnostics industry expected to reach $17.4 billion by 2028

DUBLIN, January 17, 2022 /PRNewswire/ — The “Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report by Type (Laboratory Tests, Imaging Tests, Endoscopy, Biopsy), by End-Use, by Region and Segment Forecast , 2021-2028″ report has been added to from ResearchAndMarkets.com offer.

The global liver cancer diagnostics market size is expected to reach $17.4 billion by 2028. The market is expected to grow at a CAGR of 7.5% from 2021 to 2028. Rising prevalence of liver cancer and introduction of innovative diagnostic products are propelling the growth of the market.

According to data published by Globocan, liver cancer was the 6th most common type of cancer and, in 2020, around 905,677 new cases of this life-threatening disease were diagnosed worldwide, resulting in around 830,180 deaths. The most common cause of liver cancer is chronic (long-term) infection with hepatitis C virus (HCV) or hepatitis B virus (HBV). According to WHO estimates, worldwide approximately 71.0 million people suffer from chronic HCV infection. According to the same source, in 2016, approximately 399,000 people died from cirrhosis and primary liver cancer linked to HCV infection. Such high prevalence and mortality rate of the disease has significantly increased the demand for innovative diagnostic solutions for its rapid diagnosis, thereby supporting the growth of the market.

Furthermore, continuous technological advancements in the field of oncology diagnostics and increased access to more effective diagnostic tools are expected to support the market growth throughout the forecast period. In September 2020Genetron Holdings Limited, a Chinabased on oncology diagnostics, has received FDA Breakthrough Device Designation for HCCscreen, a blood-based next-generation sequencing (NGS) test. This recently launched test is designed for the early detection of hepatocellular carcinoma (HCC) in patients suspected of being at high risk for HCC due to liver cirrhosis and/or chronic HBV infection.

Additionally, continuous public-private initiatives in several countries to increase screening for early diagnosis of various cancers including liver cancer is expected to create an enabling environment for the market to grow. In 2019, Saudi Arabia The Ministry of Health has announced that it will undertake several initiatives, including advancing screening programs, improving cancer awareness and establishing new oncology centers in the region. In 2019, Cleveland Clinic Abu Dhabi announced the introduction of an enhanced range of liver cancer services in the country to meet growing demand.

Highlights of the Liver Cancer Diagnostics Market Report

  • By type of test, the laboratory test segment has emerged as the largest segment in 2020 due to its increased demand for effective diagnosis of hepatocellular carcinoma
  • On the basis of end-use, the hospital and diagnostic laboratory segment accounted for the major revenue share during the forecast period, as they are the major centers for the diagnosis and treatment of all chronic diseases.
  • North America dominated the market and accounted for the largest revenue share in 2020. Better knowledge of hepatocellular carcinoma and high adoption of new technologies facilitate the dominance of this region over the forecast period
  • In Asia Pacific, the market is estimated to exhibit the fastest growth during the study period. This strong growth can be attributed to the presence of a huge target population and the development of health infrastructures in emerging countries.

Main topics covered:

Chapter 1. Methodology and scope

Chapter 2. Executive Summary

Chapter 3. Liver Cancer Diagnostics Market Variables, Trends and Scope
3.1 Market Lineage Prospects
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Mapping Penetration and Growth Prospects
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Increasing prevalence of liver cancer
3.3.1.2 Technological advances
3.3.1.3 Growing initiatives taken by public and private organizations
3.3.1.4 Increased prevalence of liver cancer risk factors
3.3.2 Market Restraint Analysis
3.3.2.1 High cost of diagnostic imaging
3.3.2.2 Radiation exposure that may limit the use of Ct
3.3.3 Industry Challenges
3.3.3.1 Lack of evidence on the effectiveness of whole-body liver cancer diagnostics
3.3.4 Industry Opportunities
3.3.4.1 Growing Focus on Expanding Liver Cancer Diagnostic Applications
3.4 Liver Cancer Diagnostics Market Analysis Tools
3.4.1 Industry Analysis – Porter’s
3.4.1.1 Supplier supply
3.4.1.2 Purchasing power
3.4.1.3 Threat of substitution
3.4.1.4 Threat of new entrants
3.4.1.5 Competitive Rivalry
3.4.2 PESTEL analysis
3.4.2.1 Political landscape
3.4.2.2 Environmental landscape
3.4.2.3 Social landscape
3.4.2.4 Technology landscape
3.4.2.5 Legal landscape

Chapter 4. Liver Cancer Diagnostics Market – Competitive Analysis
4.1 Recent Developments and Impact Analysis, by Major Market Players
4.2 Vendor landscape
4.2.1 List of Major Distributors and Channel Partners
4.3 Public enterprises
4.3.1 Company Market Position Analysis
4.3.2 Competitive Scorecard Analysis
4.4 Private companies
4.4.1 List of Major Emerging Companies
4.4.2 Map of the regional network
4.4.3 Company Market Position Analysis

Chapter 5. Liver Cancer Diagnostics Market: Test Type Estimates and Trend Analysis
5.1 Definition and scope
5.2 Test Types Market Share Analysis, 2020 & 2028
5.3 Segment Dashboard
5.4 Global Liver Cancer Diagnostics Market, by Test Type, 2016 to 2028
5.5 Market Size & Forecast and Trend Analysis, 2016 to 2028
5.5.1 Laboratory tests
5.5.1.1 Laboratory Testing Market Estimates and Forecast, 2016 to 2028 (USD Million)
5.5.1.2 Biomarkers
5.5.1.2.1 Biomarkers Market Estimates and Forecast, 2016 to 2028 (USD Million)
5.5.1.2.2 Oncofetal and glycoprotein antigens
5.5.1.2.2.1 Oncofetal and Glycoprotein Antigens Market estimates and forecast, 2016-2028 (USD Million)
5.5.1.2.3 Enzymes and isoenzymes
5.5.1.2.3.1 Enzymes and Isoenzymes Market estimates and forecast, 2016-2028 (USD Million)
5.5.1.2.4 Growth factors and receptors
5.5.1.2.4.1 Growth Factors and Receptors Market Estimates and Forecast, 2016-2028 (USD Million)
5.5.1.2.5 Molecular markers
5.5.1.2.5.1 Molecular Markers Market Estimates and Forecast, 2016 to 2028 (USD Million)
5.5.1.2.6 Pathological biomarkers
5.5.1.2.6.1 Disease Biomarkers Market Estimates and Forecast, 2016 to 2028 (USD Million)
5.5.1.3 Blood tests
5.5.1.3.1 Blood Testing Market Estimates and Forecast, 2016 to 2028 (USD Million)
5.5.2 Imaging tests
5.5.2.1 Imaging Testing Market Estimates and Forecast, 2016 to 2028 (USD Million)
5.5.3 Endoscopy
5.5.3.1 Endoscopy Market Estimates and Forecast, 2016 to 2028 (USD Million)
5.5.4 Biopsy
5.5.4.1 Biopsy Market Estimates and Forecast, 2016 to 2028 (USD Million)
5.5.5 Others
5.5.5.1 Other market estimates and forecast, 2016-2028 (USD Million)

Chapter 6. Liver Cancer Diagnostics Market: End-Use Estimates and Trend Analysis
6.1 Definition and scope
6.2 End-Use Market Share Analysis, 2020 & 2026
6.3 Segment Dashboard
6.4 Global Liver Cancer Diagnostics Market, by end use, from 2016 to 2026
6.5 Market Size & Forecast and Trend Analysis, 2016 to 2026
6.5.1 Hospitals and diagnostic laboratories
6.5.1.1 Hospital and Diagnostic Laboratory Market estimates and forecast, 2016-2028 (USD Million)
6.5.2 Academic and research institutes
6.5.2.1 Academic and research institutes market estimates and forecast, 2016-2028 (USD Million)
6.5.3 Pharmaceutical laboratories and cro
6.5.3.1 Pharmaceutical and CRO Laboratories Market Estimates and Forecast, 2016 to 2028 (USD Million)

Chapter 7. Liver Cancer Diagnostics Market: Regional Estimates and Trend Analysis

Chapter 8. Company Profile
8.1 Company Profiles
8.1.1 Abbott Laboratories
8.1.1.1 Presentation of the company
8.1.1.2 Financial performance
8.1.1.3 Product Benchmarking
8.1.1.4 Strategic initiatives
8.1.2 F. Hoffmann-La Roche Ltd.
8.1.2.1 Presentation of the company
8.1.2.2 Financial performance
8.1.2.3 Product Benchmarking
8.1.2.4 Strategic initiatives
8.1.3 Qiagen SA
8.1.3.1 Presentation of the company
8.1.3.2 Financial performance
8.1.3.3 Product Benchmarking
8.1.3.4 Strategic initiatives
8.1.4 Thermo Fisher Scientific, Inc.
8.1.4.1 Presentation of the company
8.1.4.2 Financial performance
8.1.4.3 Product Benchmarking
8.1.4.4 Strategic initiatives
8.1.5 Siemens Healthineers
8.1.5.1 Presentation of the company
8.1.5.2 Financial performance
8.1.5.3 Product Benchmarking
8.1.5.4 Strategic initiatives
8.1.6 Becton Dickinson & Company
8.1.6.1 Presentation of the company
8.1.6.2 Financial performance
8.1.6.3 Product Benchmarking
8.1.6.4 Strategic initiatives
8.1.7 Illumina, Inc.
8.1.7.1 Presentation of the company
8.1.7.2 Financial performance
8.1.7.3 Product Benchmarking
8.1.7.4 Strategic initiatives
8.1.8 Koninklijke Philips NV
8.1.8.1 Presentation of the company
8.1.8.2 Financial performance
8.1.8.3 Product Benchmarking
8.1.8.4 Strategic initiatives
8.1.9 Epigenomic Ag
8.1.9.1 Company Overview
8.1.9.2 Financial performance
8.1.9.3 Product Benchmarking
8.1.9.4 Strategic initiatives
8.1.10 Fujifilm medical systems United StatesInc.
8.1.10.1 Company Overview
8.1.10.2 Financial performance
8.1.10.3 Product Benchmarking
8.1.10.4 Strategic initiatives

For more information on this report, visit https://www.researchandmarkets.com/r/d2afcl

Media Contact:

Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716

SOURCE Research and Markets

Comments are closed.